



# Zoster Vaccines Session: Introduction

**ACIP Meeting**

**October 20, 2021**

Camille Nelson Kotton, MD  
Chair, Herpes Zoster Work Group

# 2021 Herpes Zoster Work Group

## ACIP Members

Camille Nelson Kotton, MD (Chair)

Lynn Bahta, RN, MPH

Grace Lee, MD, MPH

## Ex Officio Members

Paula Agger, MD, MPH

FDA

Jeffrey Cohen, MD

NIH

Darcie Everett, MD, MPH

FDA

Jeffrey Kelman, MD

CMS

## Liaison Representatives

Carol Baker, MD

IDSA

Mary Pat Friedlander, MD

AAFP

Sandra Fryhofer, MD

ACP/AMA

Elizabeth Rausch-Phung, MD, MPH

AIM

William Schaffner, MD

NFID

Kenneth Schmader, MD

AGS

Adam Welch, PharmD

APhA

## Invited Consultants

Edward Belongia, MD

Al Benson, MD

Paul Cieslak, MD

Jeffrey Curtis, MD, MPH

Jay Fishman, MD

Rafael Harpaz, MD, MPH

Kelly Moore, MD, MPH

Vicki Morrison, MD


Steven Pergam, MD

Lisa Prosser, PhD

## CDC Lead

Tara Anderson, DVM, MPH, PhD

# Timeline of Recombinant Zoster Vaccine (RZV, Shingrix)



Abbreviations: HZ-Herpes Zoster; IC-Immunocompromised; RZV-Recombinant Zoster Vaccine; EtR-Evidence to Recommendations Framework

# Policy Question

- **Should adults aged  $\geq 19$  years who are or will be immunodeficient or immunosuppressed due to disease or therapy be recommended to receive two doses of recombinant zoster vaccine for the prevention of herpes zoster and its complications?**
  
- **Including but not limited to:**
  1. Hematopoietic stem cell transplant (HSCT) recipients
  2. Patients with hematologic malignancies (HM)
  3. Renal or other solid organ transplant (SOT) recipients
  4. Patients with solid tumor malignancies (STM)
  5. People living with HIV
  6. Patients with primary immunodeficiencies, autoimmune and inflammatory conditions, and taking immunosuppressive medications/therapies

# PICO Question

<b>Population</b>	Immunocompromised (IC) adults aged $\geq 19$ years
<b>Intervention</b>	Recombinant zoster vaccine (RZV), 2 doses at least 4 weeks apart*
<b>Comparison</b>	No vaccine
<b>Critical Outcomes</b>	<ul style="list-style-type: none"><li>• Herpes Zoster (HZ)</li><li>• Serious Adverse Events (SAEs)</li></ul>
<b>Important Outcomes</b>	<ul style="list-style-type: none"><li>• Postherpetic Neuralgia (PHN)</li><li>• HZ-Related Hospitalization</li><li>• Immune-Mediated Disease (IMD)</li><li>• Reactogenicity (Grade 3)</li><li>• Graft versus Host Disease (HSCT)</li><li>• Graft Rejection (SOT)</li></ul>

\*First dose at Month 0 followed by a second dose 2 to 6 months later; For individuals who are or will be immunodeficient or immunosuppressed and who would benefit from a shorter vaccination schedule: First dose at Month 0 followed by a second dose 1 to 2 months later.

# September 2021 ACIP Meeting

- Economics of vaccinating IC 19–49-year-old adults against HZ in the US
- Preliminary EtR regarding use of RZV in IC adults ≥19 years

EtR Domain	Question
Public Health Problem	Is the problem of public health importance?
Benefits and Harms	How substantial are the desirable anticipated effects?
	How substantial are the undesirable anticipated effects?
	Do the desirable effects outweigh the undesirable effects?
Values	Does the target population feel the desirable effects are large relative to the undesirable effects?
	Is there important variability in how patients value the outcomes?
Acceptability	Is the intervention acceptable to key stakeholders?
Resource Use	Is the intervention a reasonable and efficient allocation of resources?
Equity	What would be the impact of the intervention on health equity?
Feasibility	Is the intervention feasible to implement?

# Activities since September 2021 ACIP Meeting

- **Two work group meetings**
- **Reviewed and discussed**
  - September 2021 ACIP feedback
  - EtR updates
  - Considerations for use of RZV in IC adults
  - Proposed policy options

# Today's Session

- **WG Interpretation of the EtR Regarding Use of RZV in Immunocompromised Adults, Considerations for Use, and Proposed Policy Options**
- **Discussion**
- **ACIP vote later in meeting**



# Acknowledgments

- **ACIP HZWG:** Paula Agger, Robin Avery, Lynn Bahta, Carol Baker, Edward Belongia, Al Benson, Paul Cieslak, Jeff Cohen, Jeff Curtis, Jeff Duchin, Darcie Everett, Jay Fishman, Mary Pat Friedlander, Sandra Fryhofer, Rafael Harpaz, Jeff Kelman, Grace Lee, Vicki Morrison, Kelly Moore, Steve Pergam, Lisa Prosser, Elizabeth Rausch-Phung, Bill Schaffner, Ken Schmader, Adam Welch
- **HZWG CDC Lead:** Tara Anderson
- **CDC, Other Contributors:** Jessica Anderson, Stephanie Bialek, Doug Campos-Outcalt, Tom Clark, Amanda Cohn, Janine Cory, Kathleen Dooling, Jonathan Duffy, Richard Forshee, Jack Gersten, Angela Guo, Theresa Harrington, Alexandra Hess, Laura Hurley, Shainoor Ismail, Lisa Jackson, Tara Jatlaoui, Andrew Kroger, Andrew Leidner, Jessica Leung, Megan Lindley, Jessica MacNeil, Mona Marin, Karen Mason, Nina Masters, Rebecca Morgan, Jennifer Nelson, Ismael Ortega-Sanchez, Paul Rota, Coleman Rotstein, Jeanne Santoli, Leah Shepersky, Tom Shimabukuro, John Su, Joanna Taliano, Megan Wallace, Eric Weintraub

# Thank You

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

